A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants with body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²)
Must be males or females not of childbearing potential
Part B and C - Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
Participants Must Not:
Participants must not have had heart disease or other heart conditions like heart attack, heart failure or stroke
Part B and C -
Have had more than 1 emergency treatment or hospitalization for very low blood sugar or very high blood sugar level in the past 6 months
Have been treated with Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA), Dipeptidyl Peptidase 4 (DPP4) inhibitor, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors within the previous 3 months
Participants who received systemic or inhaled glucocorticoid therapy
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo